Key Takeaways
- Shares of Travere Therapeutics (TVTX) climbed 44% following regulatory clearance for FILSPARI in focal segmental glomerulosclerosis
- FILSPARI represents the inaugural FDA-sanctioned therapy specifically for FSGS patients
- Regulatory clearance applies to patients aged 8 years and above who lack nephrotic syndrome
- More than 30,000 U.S. patients could qualify for treatment under the approved indication
- Guggenheim analysts increased their TVTX price objective to $54 while reaffirming their Buy recommendation
Shares of Travere Therapeutics (TVTX) surged 44% during Tuesday’s session following the Food and Drug Administration’s authorization of FILSPARI (sparsentan) for treating focal segmental glomerulosclerosis — a rare kidney condition that previously had zero approved therapeutic options.
Travere Therapeutics, Inc., TVTX
The regulatory authorization encompasses adult patients plus pediatric cases starting at age 8 with FSGS who lack nephrotic syndrome markers. FILSPARI now stands as the sole FDA-authorized medication targeting this particular kidney disease.
This regulatory win represents FILSPARI’s second rare kidney disease clearance, complementing its existing authorization for IgA nephropathy treatment.
According to Travere’s assessment, over 30,000 FSGS patients across the United States could qualify for treatment — specifically those not exhibiting the three simultaneous biomarkers characteristic of nephrotic syndrome.
Clinical Trial Results Behind the Approval
Regulatory authorization stemmed from results of the Phase 3 DUPLEX Study, characterized as the most comprehensive interventional clinical investigation ever conducted in FSGS populations.
Participants receiving FILSPARI demonstrated a 46% decline in proteinuria levels measured from study initiation through Week 108. Comparatively, subjects taking maximum-dosage irbesartan experienced a 30% reduction.
Within the patient subset specifically lacking nephrotic syndrome characteristics, FILSPARI achieved a 48% proteinuria decrease compared with 27% for the comparator therapy.
Patients in this subset receiving FILSPARI additionally exhibited eGFR benefits, showing a treatment advantage of 1.1 mL/min/1.73 m² measured at the 108-week mark.
Safety data revealed FILSPARI’s tolerability profile matched irbesartan across both adult and younger patient populations — a favorable outcome expected to support commercial adoption.
Wall Street’s Response
Guggenheim’s Vamil Divan elevated his TVTX price objective to $54 from a previous $49 target while maintaining his Buy stance after the regulatory announcement.
Divan emphasized that the approved labeling exceeded expectations, highlighting how the authorized patient population proved more expansive than market consensus had anticipated.
The label specifically encompasses both primary and secondary FSGS presentations — moving beyond just the primary and genetic variants that analysts and company leadership had previously modeled as the probable authorization scope.
This expanded indication creates a substantially larger revenue opportunity than many investors had factored into valuations.
TipRanks reports an additional analyst Buy recommendation carrying a $47 price objective for the equity, while assigning a Buy technical signal rating.
Following Tuesday’s price movement, TVTX’s market capitalization reached approximately $2.67 billion.
The FDA issued its approval on April 13, 2026, with the stock’s dramatic response occurring throughout Tuesday’s trading hours.
